MedTrace Logo

Role of Bilirubin Molecular Species in Hepatic Encephalopathy and Acute-on-chronic Liver Failure

NCT05566548 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-10-07

No results posted yet for this study

Summary

It has been identified that impaired liver function, as occurs in patients with liver cirrhosis, prevents proper conjugation of glucuronic acid with bilirubin; as a result, unconjugated bilirubin accumulates in the blood, and conjugated bilirubin is markedly altered to form diglucuronides or monoglucuronides. However, in the development and progress of acute-on-chronic liver failure (ACLF) there is not enough information about these processes and the possible concentration levels that they can take.

Also Hepatic encephalopathy (HE) is a reversible complication, but with a high mortality rate in patients with acute or chronic liver failure, as well as a consequence of the formation of portosystemic shunts.

Conditions

  • Hepatic Encephalopathy
  • Acute-On-Chronic Liver Failure

Interventions

DIAGNOSTIC_TEST

Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species

It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.

Sponsors & Collaborators

  • Medica Sur Clinic & Foundation

    lead OTHER

Principal Investigators

  • Nahum Mendez-Sanchez, MD, PhD · Medica Sur Clinic & Foundation

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-07-31
Completion
2023-08-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05566548 on ClinicalTrials.gov